Ticker Launch

Reverse merger · Completed · NRBO

NeuroBo Pharmaceuticals, Inc.

Reverse merger with Gemphire Therapeutics Inc. (GEMP)

NeuroBo Pharmaceuticals, Inc. merged into Gemphire Therapeutics Inc. (GEMP), a Nasdaq-listed clinical-stage biotech with a partial clinical hold on gemcabene, in a reverse merger that takes the private company public. The deal was announced on Jul 24, 2019 and closed on Dec 30, 2019. The combined company trades as NeuroBo Pharmaceuticals, Inc. (NRBO) on Nasdaq.

NeuroBo Pharmaceuticals is a clinical-stage biotechnology company advancing a neurodegenerative disease pipeline, built from the former private NeuroBo. It became Nasdaq-listed through its merger with Gemphire Therapeutics.

Status
Completed
Private company
NeuroBo Pharmaceuticals, Inc.
Public company
Gemphire Therapeutics Inc. (GEMP)
Public company business before
Nasdaq-listed clinical-stage biotech with a partial clinical hold on gemcabene
Announced
Jul 24, 2019
Closed
Dec 30, 2019
Combined company
NeuroBo Pharmaceuticals, Inc. (NRBO)
Exchange
Nasdaq
Sector
Biotech & pharma

More on this deal for subscribers

Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.

Then $99/month or $999/year. Cancel anytime.

Filings

Other completed reverse mergers